Cethromycin

Jump to: navigation, search
Cethromycin
Cethromycin.png
Clinical data
Routes of
administration
Oral
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC42H59N3O10
Molar mass765.931 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cethromycin (initially known as ABT-773) is a macrolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication.[1] Originally discovered and developed by Abbott, it was acquired by Advanced Life Sciences Inc. for further development.

On April 10, 2008, Advanced Life Sciences announced that, based on a productive meeting with the U.S. Food and Drug Administration (FDA), it plans to submit a New Drug Application (NDA) in the third quarter of 2008 for cethromycin to treat mild-to-moderate community acquired pneumonia.[2]

References


Linked-in.jpg